Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
60 participants
INTERVENTIONAL
2008-12-31
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis
NCT06881966
N-3 PUFA and Rheumatoid Arthritis in Korea
NCT01618019
The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
NCT01818804
Marine Oils and Arthritis
NCT00805116
Effect of Palmitoleic Acid on C-reactive Protein
NCT03625427
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fish oil
3g/d
Fish oil, gamma-linolenic acid
3 g/d DHA + EPA
Gamma-linolenic Acid
3g/d gamma-linolenic acid
Fish oil, gamma-linolenic acid
3 g/d DHA + EPA
Fish oil plus GLA
1.5 g/d DHA + EPA plus 1.5g/d gamma-linolenic acid
Fish oil, gamma-linolenic acid
3 g/d DHA + EPA
Olive oil
3 g/d olive oil
Fish oil, gamma-linolenic acid
3 g/d DHA + EPA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fish oil, gamma-linolenic acid
3 g/d DHA + EPA
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Non-compliance
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Jena
OTHER
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abteilung für Naturheilkunde Charité
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rainer Stange, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Immanuel Krankenhaus and Charite Berlin
References
Explore related publications, articles, or registry entries linked to this study.
Dawczynski C, Hackermeier U, Viehweger M, Stange R, Springer M, Jahreis G. Incorporation of n-3 PUFA and gamma-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial. Lipids Health Dis. 2011 Aug 4;10:130. doi: 10.1186/1476-511X-10-130.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Charite-n-3-n-6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.